天演药业上涨4.61%，报2.27美元/股，总市值1.07亿美元

Core Viewpoint - Tianyan Pharmaceuticals (ADAG) is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies based on original antibodies, utilizing a powerful platform that combines computational biology and artificial intelligence [1]. Financial Performance - As of December 31, 2024, Tianyan Pharmaceuticals reported total revenue of $103,200, a year-over-year decrease of 99.43% [1]. - The company recorded a net loss attributable to shareholders of $33.4241 million, representing a year-over-year decline of 76.41% [1]. Company Overview - Tianyan Pharmaceuticals is a platform-driven biopharmaceutical company that develops clinical products and aims to discover and create new cancer immunotherapies [1]. - The company’s antibody discovery engine, known as the "Dynamic Precision Library," is advancing its product pipeline and aims to develop potentially innovative or best-in-class products globally [1].